

NEWSLETTER

CHEMICAL & PHARMACEUTICAL

13 - 19 July 2026



China Imposes Temporary Ban on Helium Exports

China will impose a temporary ban on the export of helium under relevant provisions of its Foreign Trade Law, according to a statement issued by the Ministry of Commerce. Helium is widely used in such fields as semiconductor manufacturing, optical fiber manufacturing, aerospace, low-temperature superconductivity research, and high-end welding and testing. **(Xinhua)**

Shengquan Group Raises Prices of PPO, MPPO, and Other Oligomers on July 13th

Shengquan Group, a core producer of phenolic resins and polyphenylene ethers, issued a price adjustment notice. The company confirmed that, effective July 13, 2026, it will comprehensively raise the sales prices of its entire series of oligomer products. The price adjustment range is 15% to 20%, covering all supply channels, including regular orders and long-term contracts in various regions of China. **(ChemNet Chemical Headlines)**

The Expansion of the Weifang Binhai Chemical Industrial Park in Shandong Province

The Shandong Provincial People's Government officially issued the "Approval for the Expansion of the Weifang Binhai Chemical Industrial Park," approving in principle the expansion of the park's approved area. The total approved area of the park has increased to 56.2987 square kilometers, further expanding the park's development space and injecting new momentum into the high-quality development of the regional chemical industry. **(ChemNet Chemical Headlines)**

China's First Domestically Produced GLP-1 (Glucagon-Like Peptide-1) Oral Drug Approved For Diabetes

China has approved the country's first homegrown oral GLP-1 receptor agonist for type 2 diabetes treatment. Clinical trials showed significant reductions in HbA1c levels and body weight compared with placebo groups. The launch is expected to lower treatment costs and expand patient access across domestic markets. Domestic production will reduce dependence on imported innovative diabetes therapies. **(National Medical Products Administration)**

China Grants Priority Review To mRNA-based Cancer Vaccine Candidate

A domestic biopharmaceutical company has received priority review status for its mRNA-based (Messenger Ribonucleic Acid) personalized cancer vaccine targeting advanced melanoma. Early-phase data indicated promising safety profiles and durable immune responses in patients with high recurrence risk. If approved, it would be China's first mRNA therapeutic beyond infectious disease applications. **(Center for Drug Evaluation)**